Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yong Shim

Showing results (271-280 of 290) with videos related to

Pageof 29
Sort By:
Cancer Research and Treatment|December 11, 2025
Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup-Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOWKeun-Wook Lee, Sang Cheul Oh, Jong Gwang Kim, et al.
Cancer|May 29, 2023
A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomasJiyun Lee, Sehhoon Park, Hyun Ae Jung, et al.
Korean Journal of Family Medicine|December 6, 2021
Clinical Practice Guidelines for Managing Frailty in Community-Dwelling Korean Elderly Adults in Primary Care SettingsHyo-Sun You, Yu-Jin Kwon, Sunyoung Kim, et al.
Nature Medicine|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trialTina Cascone, Laura Bonanno, Florian Guisier, et al.
Cancer Research and Treatment|July 3, 2025
Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4)Yoon-Koo Kang, Min-Hee Ryu, Do-Youn Oh, et al.
Cancer Letters|June 26, 2024
Targeting S6K/NFκB/SQSTM1/Polθ signaling to suppress radiation resistance in prostate cancerAlison Clark, Michelle R Villarreal, Shih-Bo Huang, et al.
Han'Guk Hosup'Isu Wanhwa Uiryo Hakhoe Chi = the Korean Journal of Hospice and Palliative Care|July 27, 2023
Clinical Practice Guideline for Care in the Last Days of LifeJinyoung Shin, Yoon Jung Chang, So-Jung Park, et al.
Clinical Colorectal Cancer|October 27, 2016
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC StudyAnn-Lii Cheng, Gerardo Cornelio, Lin Shen, et al.
Cancer Research and Treatment|July 4, 2023
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean SubsetKi Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, et al.
The Korean Journal of Internal Medicine|November 28, 2017
The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 studyJae Ho Byun, Joong Bae Ahn, Sun Young Kim, et al.
Pageof 29

Showing results (271-280 of 290) with videos related to

Sort By:
Pageof 29
Cancer Research and Treatment|December 11, 2025
Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup-Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOWKeun-Wook Lee, Sang Cheul Oh, Jong Gwang Kim, et al.
Cancer|May 29, 2023
A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomasJiyun Lee, Sehhoon Park, Hyun Ae Jung, et al.
Korean Journal of Family Medicine|December 6, 2021
Clinical Practice Guidelines for Managing Frailty in Community-Dwelling Korean Elderly Adults in Primary Care SettingsHyo-Sun You, Yu-Jin Kwon, Sunyoung Kim, et al.
Nature Medicine|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trialTina Cascone, Laura Bonanno, Florian Guisier, et al.
Cancer Research and Treatment|July 3, 2025
Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4)Yoon-Koo Kang, Min-Hee Ryu, Do-Youn Oh, et al.
Cancer Letters|June 26, 2024
Targeting S6K/NFκB/SQSTM1/Polθ signaling to suppress radiation resistance in prostate cancerAlison Clark, Michelle R Villarreal, Shih-Bo Huang, et al.
Han'Guk Hosup'Isu Wanhwa Uiryo Hakhoe Chi = the Korean Journal of Hospice and Palliative Care|July 27, 2023
Clinical Practice Guideline for Care in the Last Days of LifeJinyoung Shin, Yoon Jung Chang, So-Jung Park, et al.
Clinical Colorectal Cancer|October 27, 2016
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC StudyAnn-Lii Cheng, Gerardo Cornelio, Lin Shen, et al.
Cancer Research and Treatment|July 4, 2023
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean SubsetKi Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, et al.
The Korean Journal of Internal Medicine|November 28, 2017
The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 studyJae Ho Byun, Joong Bae Ahn, Sun Young Kim, et al.
Pageof 29